Regeneron Pharmaceuticals, Inc. Gross Profit 2008–2025
Regeneron Pharmaceuticals, Inc. reported $6.15B of gross profit for fiscal 2019. That was 25.4% higher than fiscal 2018. Compared with fiscal 2014, the change was +128.8%.
| Fiscal year | Gross Profit | Gross margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | — | — | — |
| FY 2024 | — | — | — |
| FY 2023 | — | — | — |
| FY 2022 | — | — | — |
| FY 2021 | — | — | — |
| FY 2020 | — | — | — |
| FY 2019 | $6.15B | 93.9% | +25.4% |
| FY 2018 | $4.91B | 95.4% | -13.4% |
| FY 2017 | $5.67B | 96.6% | +21.5% |
| FY 2016 | $4.67B | 96.0% | +20.8% |
| FY 2015 | $3.86B | 94.1% | +43.5% |
| FY 2014 | $2.69B | 95.4% | +35.4% |
| FY 2013 | $1.99B | 94.4% | +53.5% |
| FY 2012 | $1.29B | 93.9% | +193.1% |
| FY 2011 | $441.61M | 99.1% | -3.4% |
| FY 2010 | $456.98M | 99.5% | +21.0% |
| FY 2009 | $377.58M | 99.6% | +59.0% |
| FY 2008 | $237.53M | 99.6% | — |
Source: Regeneron Pharmaceuticals, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open REGN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Regeneron Pharmaceuticals, Inc. reported $6.15B of gross profit for fiscal 2019. That was 25.4% higher than fiscal 2018. Compared with fiscal 2014, the change was +128.8%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Regeneron Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeRegeneron Pharmaceuticals, Inc. — frequently asked questions
What is Regeneron Pharmaceuticals, Inc.'s gross profit?
Regeneron Pharmaceuticals, Inc. (REGN) reported gross profit of $6.15B for fiscal year 2019, per its SEC filings.
How has Regeneron Pharmaceuticals, Inc.'s gross profit changed over time?
Between fiscal 2008 and 2025, REGN's gross profit grew at roughly 21.1% per year (compound annual rate), from $237.53M to $6.15B.
Where does this data come from?
Figures are computed from Regeneron Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.